<p>Intellia Therapeutics, Inc.（納斯達克代碼：NTLA - 獲取免費報告）在週五的午盤交易中股價下跌了 4.3%。該股票最低交易價為 8.93 美元，最後交易價為 9.06 美元。在交易中，共成交 436,341 股，較平均交易量 2,550,550 股下降了 83%。該股票此前收盤價為 9.46 美元。</p>
<p>獲取 <strong>Intellia Therapeutics</strong> 的提醒：</p>
<h2>華爾街分析師觀點</h2>
<ul>
<li>分析師認為這些股票的價值可能翻倍</li>
</ul>
<p>NTLA 一直是多份分析師報告的主題。Guggenheim 將 Intellia Therapeutics 的目標價從 55.00 美元下調至 45.00 美元，並在 5 月 12 日的報告中給予該股票 “買入” 評級。HC Wainwright 在週二的研究報告中重申了 “買入” 評級，並對 Intellia Therapeutics 的股票設定了 30.00 美元的目標價。Wolfe Research 在 4 月 21 日的研究報告中將 Intellia Therapeutics 的股票評級從 “同業表現” 上調至 “跑贏大盤”，並設定了 21.00 美元的目標價。Barclays 在 2 月 28 日的報告中將 Intellia Therapeutics 的目標價從 55.00 美元下調至 26.00 美元，並給予該股票 “增持” 評級。最後，Wall Street Zen 在 3 月 3 日的研究報告中將 Intellia Therapeutics 的股票評級下調至 “賣出”。兩位分析師給予該股票 “賣出” 評級，六位給予 “持有” 評級，十三位給予 “買入” 評級，還有一位給予 “強烈買入” 評級。根據 MarketBeat.com 的數據，Intellia Therapeutics 目前的平均評級為 “適度買入”，平均目標價為 36.90 美元。</p>
<p><strong>查看我們對 NTLA 的最新股票分析</strong></p>
<h2>Intellia Therapeutics 股票表現</h2>
<ul>
<li>2 只基因編輯股票有望在 2025 年強勢反彈</li>
</ul>
<p>該公司的市值為 9.5037 億美元，市盈率為-1.68，貝塔值為 2.33。該公司的 50 日移動平均價格為 7.98 美元，200 日移動平均價格為 10.63 美元。</p>
<p>Intellia Therapeutics（納斯達克代碼：NTLA - 獲取免費報告）最近在 5 月 8 日發佈了其財報。該公司報告本季度每股收益為（1.10 美元），超出市場共識預期的（1.26 美元）0.16 美元。該公司本季度的收入為 1663 萬美元，而分析師預期為 1139 萬美元。去年同期，該公司每股收益為（1.12 美元）。Intellia Therapeutics 的收入同比下降了 42.6%。平均而言，股票研究分析師預計 Intellia Therapeutics, Inc.在當前財年將發佈每股收益為-5.07 美元。</p>
<h2>機構投資者對 Intellia Therapeutics 的看法</h2>
<ul>
<li>3 只快速增長的股票分析師認為價格將翻倍</li>
</ul>
<p>一些機構投資者最近增加或減少了對該股票的持股。Barclays PLC 在第三季度將其在 Intellia Therapeutics 的持股增加了 17.7%。Barclays PLC 現在擁有 292,795 股該公司的股票，價值 6,017,000 美元，此前在上個季度又購買了 44,022 股。SG Americas Securities LLC 在第四季度將其在 Intellia Therapeutics 的持股增加了 85.7%。SG Americas Securities LLC 現在擁有 44,838 股該公司的股票，價值 523,000 美元，此前在上個季度又收購了 20,694 股。KBC Group NV 在第四季度將其在 Intellia Therapeutics 的持股增加了 62.4%。KBC Group NV 現在擁有 6,093 股該公司的股票，價值 71,000 美元，此前在此期間又收購了 2,340 股。中國泛海資產管理有限公司在第四季度將其在 Intellia Therapeutics 的持股增加了 10.5%。中國泛海資產管理有限公司現在擁有 21,596 股該公司的股票，價值 252,000 美元，此前在此期間又收購了 2,059 股。最後，Empowered Funds LLC 在第四季度收購了 Intellia Therapeutics 的新股份，價值 185,000 美元。88.77% 的股票由機構投資者和對沖基金持有。</p>
<h2>關於 Intellia Therapeutics</h2>
<p>（獲取免費報告）</p>
<p>Intellia Therapeutics, Inc.是一家基因編輯公司，專注於治癒性療法的開發。該公司的體內項目包括 NTLA-2001，目前正在進行治療轉甲狀腺素澱粉樣變的 1 期臨牀試驗；NTLA-2002 用於治療遺傳性血管性水腫；以及 NTLA-3001 用於與α-1 抗胰蛋白酶缺乏相關的肺病。</p>
<h2>精選文章</h2>
<ul>
<li>五隻我們認為比 Intellia Therapeutics 更好的股票</li>
<li>如何找到值得投資和交易的便士股票</li>
<li>Williams-Sonoma：一項基本面良好的買入機會</li>
<li>5 只值得考慮的高評級分紅股票</li>
<li>Advance Auto Parts 因意外盈利而上漲</li>
<li>股票行業對成功投資的重要性</li>
<li>DraftKings 的三月瘋狂失誤：華爾街看到 +50% 的上漲空間</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送電子郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Intellia Therapeutics 嗎？</h2>
<p>在你考慮投資 Intellia Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前進行購買……而 Intellia Therapeutics 並不在名單上。</p>
<p>雖然 Intellia Therapeutics 目前在分析師中獲得 “適度買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

Intellia治療

<p>Intellia Therapeutics（納斯達克代碼：NTLA）股價在午盤交易中下跌 4.3%，至 9.06 美元，交易量顯著減少。分析師意見不一，古根海姆將其目標價下調至 45 美元，而 HC Wainwright 則維持 30 美元的目標。該公司報告的季度每股虧損為 1.10 美元，超出預期，但收入同比下降 42.6%。機構投資者持有 88.77% 的股份，儘管近期表現不佳，但仍顯示出強烈的投資興趣</p>

<p>Intellia Therapeutics, Inc. (NASDAQ:NTLA - Get Free Report) shares fell 4.3% during mid-day trading on Friday . The stock traded as low as $8.93 and last traded at $9.06. 436,341 shares traded hands during trading, a decline of 83% from the average session volume of 2,550,550 shares. The stock had previously closed at $9.46.</p>
<div class="lb-trans"><p>Intellia Therapeutics, Inc.（納斯達克代碼：NTLA - 獲取免費報告）在週五的午盤交易中股價下跌了 4.3%。該股票最低交易價為 8.93 美元，最後交易價為 9.06 美元。在交易中，共成交 436,341 股，較平均交易量 2,550,550 股下降了 83%。該股票此前收盤價為 9.46 美元。</p>
</div><p>Get <strong>Intellia Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Intellia Therapeutics</strong> 的提醒：</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><ul>
<li>Analysts Think These Stocks Could More Than Double in Value</li>
</ul>
<div class="lb-trans"><ul>
<li>分析師認為這些股票的價值可能翻倍</li>
</ul>
</div><p>NTLA has been the topic of a number of analyst reports. Guggenheim lowered their price objective on Intellia Therapeutics from $55.00 to $45.00 and set a &#34;buy&#34; rating on the stock in a report on Monday, May 12th. HC Wainwright restated a &#34;buy&#34; rating and issued a $30.00 price objective on shares of Intellia Therapeutics in a research note on Tuesday. Wolfe Research upgraded shares of Intellia Therapeutics from a &#34;peer perform&#34; rating to an &#34;outperform&#34; rating and set a $21.00 target price on the stock in a research note on Monday, April 21st. Barclays dropped their target price on shares of Intellia Therapeutics from $55.00 to $26.00 and set an &#34;overweight&#34; rating on the stock in a report on Friday, February 28th. Finally, Wall Street Zen raised shares of Intellia Therapeutics to a &#34;sell&#34; rating in a research report on Monday, March 3rd. Two analysts have rated the stock with a sell rating, six have given a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Intellia Therapeutics presently has an average rating of &#34;Moderate Buy&#34; and an average price target of $36.90.</p>
<div class="lb-trans"><p>NTLA 一直是多份分析師報告的主題。Guggenheim 將 Intellia Therapeutics 的目標價從 55.00 美元下調至 45.00 美元，並在 5 月 12 日的報告中給予該股票 “買入” 評級。HC Wainwright 在週二的研究報告中重申了 “買入” 評級，並對 Intellia Therapeutics 的股票設定了 30.00 美元的目標價。Wolfe Research 在 4 月 21 日的研究報告中將 Intellia Therapeutics 的股票評級從 “同業表現” 上調至 “跑贏大盤”，並設定了 21.00 美元的目標價。Barclays 在 2 月 28 日的報告中將 Intellia Therapeutics 的目標價從 55.00 美元下調至 26.00 美元，並給予該股票 “增持” 評級。最後，Wall Street Zen 在 3 月 3 日的研究報告中將 Intellia Therapeutics 的股票評級下調至 “賣出”。兩位分析師給予該股票 “賣出” 評級，六位給予 “持有” 評級，十三位給予 “買入” 評級，還有一位給予 “強烈買入” 評級。根據 MarketBeat.com 的數據，Intellia Therapeutics 目前的平均評級為 “適度買入”，平均目標價為 36.90 美元。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on NTLA</strong></p>
<div class="lb-trans"><p><strong>查看我們對 NTLA 的最新股票分析</strong></p>
</div><h2>Intellia Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>Intellia Therapeutics 股票表現</h2>
</div><ul>
<li>2 Gene-Editing Stocks Positioned for a Strong Comeback in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>2 只基因編輯股票有望在 2025 年強勢反彈</li>
</ul>
</div><p>The company has a market cap of $950.37 million, a price-to-earnings ratio of -1.68 and a beta of 2.33. The business's 50 day moving average price is $7.98 and its 200-day moving average price is $10.63.</p>
<div class="lb-trans"><p>該公司的市值為 9.5037 億美元，市盈率為-1.68，貝塔值為 2.33。該公司的 50 日移動平均價格為 7.98 美元，200 日移動平均價格為 10.63 美元。</p>
</div><p>Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($1.10) earnings per share for the quarter, beating the consensus estimate of ($1.26) by $0.16. The business had revenue of $16.63 million for the quarter, compared to analyst estimates of $11.39 million. During the same quarter last year, the firm posted ($1.12) earnings per share. Intellia Therapeutics's revenue was down 42.6% on a year-over-year basis. On average, equities research analysts expect that Intellia Therapeutics, Inc. will post -5.07 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Intellia Therapeutics（納斯達克代碼：NTLA - 獲取免費報告）最近在 5 月 8 日發佈了其財報。該公司報告本季度每股收益為（1.10 美元），超出市場共識預期的（1.26 美元）0.16 美元。該公司本季度的收入為 1663 萬美元，而分析師預期為 1139 萬美元。去年同期，該公司每股收益為（1.12 美元）。Intellia Therapeutics 的收入同比下降了 42.6%。平均而言，股票研究分析師預計 Intellia Therapeutics, Inc.在當前財年將發佈每股收益為-5.07 美元。</p>
</div><h2>Institutional Investors Weigh In On Intellia Therapeutics</h2>
<div class="lb-trans"><h2>機構投資者對 Intellia Therapeutics 的看法</h2>
</div><ul>
<li>3 Fast-Growing Stocks Analysts See Doubling in Price</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只快速增長的股票分析師認為價格將翻倍</li>
</ul>
</div><p>A number of institutional investors have recently added to or reduced their stakes in the stock. Barclays PLC boosted its stake in Intellia Therapeutics by 17.7% in the 3rd quarter. Barclays PLC now owns 292,795 shares of the company's stock valued at $6,017,000 after buying an additional 44,022 shares in the last quarter. SG Americas Securities LLC raised its stake in Intellia Therapeutics by 85.7% during the fourth quarter. SG Americas Securities LLC now owns 44,838 shares of the company's stock worth $523,000 after acquiring an additional 20,694 shares in the last quarter. KBC Group NV lifted its holdings in shares of Intellia Therapeutics by 62.4% during the fourth quarter. KBC Group NV now owns 6,093 shares of the company's stock valued at $71,000 after acquiring an additional 2,340 shares during the period. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Intellia Therapeutics by 10.5% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 21,596 shares of the company's stock valued at $252,000 after acquiring an additional 2,059 shares during the period. Finally, Empowered Funds LLC acquired a new stake in shares of Intellia Therapeutics in the 4th quarter valued at $185,000. 88.77% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一些機構投資者最近增加或減少了對該股票的持股。Barclays PLC 在第三季度將其在 Intellia Therapeutics 的持股增加了 17.7%。Barclays PLC 現在擁有 292,795 股該公司的股票，價值 6,017,000 美元，此前在上個季度又購買了 44,022 股。SG Americas Securities LLC 在第四季度將其在 Intellia Therapeutics 的持股增加了 85.7%。SG Americas Securities LLC 現在擁有 44,838 股該公司的股票，價值 523,000 美元，此前在上個季度又收購了 20,694 股。KBC Group NV 在第四季度將其在 Intellia Therapeutics 的持股增加了 62.4%。KBC Group NV 現在擁有 6,093 股該公司的股票，價值 71,000 美元，此前在此期間又收購了 2,340 股。中國泛海資產管理有限公司在第四季度將其在 Intellia Therapeutics 的持股增加了 10.5%。中國泛海資產管理有限公司現在擁有 21,596 股該公司的股票，價值 252,000 美元，此前在此期間又收購了 2,059 股。最後，Empowered Funds LLC 在第四季度收購了 Intellia Therapeutics 的新股份，價值 185,000 美元。88.77% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>About Intellia Therapeutics</h2>
<div class="lb-trans"><h2>關於 Intellia Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.</p>
<div class="lb-trans"><p>Intellia Therapeutics, Inc.是一家基因編輯公司，專注於治癒性療法的開發。該公司的體內項目包括 NTLA-2001，目前正在進行治療轉甲狀腺素澱粉樣變的 1 期臨牀試驗；NTLA-2002 用於治療遺傳性血管性水腫；以及 NTLA-3001 用於與α-1 抗胰蛋白酶缺乏相關的肺病。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than Intellia Therapeutics</li>
<li>How to find penny stocks to invest and trade</li>
<li>Williams-Sonoma: A Fundamentally Good Buy On Sale Now</li>
<li>5 Top Rated Dividend Stocks to Consider</li>
<li>Advance Auto Parts Jumps on Surprise Earnings Beat</li>
<li>Why Are Stock Sectors Important to Successful Investing?</li>
<li>DraftKings' March Madness Miss: Wall Street Sees +50% Upside</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們認為比 Intellia Therapeutics 更好的股票</li>
<li>如何找到值得投資和交易的便士股票</li>
<li>Williams-Sonoma：一項基本面良好的買入機會</li>
<li>5 只值得考慮的高評級分紅股票</li>
<li>Advance Auto Parts 因意外盈利而上漲</li>
<li>股票行業對成功投資的重要性</li>
<li>DraftKings 的三月瘋狂失誤：華爾街看到 +50% 的上漲空間</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送電子郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Intellia Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Intellia Therapeutics 嗎？</h2>
</div><p>Before you consider Intellia Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮投資 Intellia Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Intellia Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前進行購買……而 Intellia Therapeutics 並不在名單上。</p>
</div><p>While Intellia Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Intellia Therapeutics 目前在分析師中獲得 “適度買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Intellia 治療（NASDAQ:NTLA）股價下跌 4.3% - 現在是賣出的時候嗎？